Proof of Concept clinical trial for Akaza Biosciences’ Resatorvid in Acute on Chronic Liver failure patients

点击翻译按钮获取中文摘要

Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute deterioration of existing chronic liver disease, progressing to organ failure and associated with a high mortality. It usually results after a precipitating event such as trauma, surgery, variceal bleeding, or infection that may directly exaggerate liver injury. There are no approved treatments for the condition. Management of ACLF focuses on rapid treatment of the precipitating event when this can be identified and the delivery of supportive care. The 28-day mortality in patients presenting with ACLF has been estimated to be approximately 34%. RESATORVID is a new first in class therapeutic approach with previous promising efficacy and safety in sepsis clinical trials. It has a unique way of working, and there is good evidence to suggest it will provide the first ever effective and targeted treatment for ACLF patients. Akaza Biosciences Ltd intend to progress Resatorvid into a Phase 2 clinical proof-of-concept trial in ACLF patients. Success would lead to an Orphan Drug Designation and eventual registration, and market availability in 2022\.